Jubilant HollisterStier Launches $132 Million Sterile Injectable Manufacturing Line in Washington
核心洞察
Jubilant HollisterStier LLC has successfully commissioned its third sterile fill and finish line at its Spokane facility with a $132 million investment, featuring advanced isolator technology for enhanced sterility assurance.
The new production line adds 50% manufacturing capacity to the facility and is expected to reach full utilization within three years amid strong demand from major pharmaceutical companies.
With a fourth line planned, the company is on track to double its total sterile injectable manufacturing capacity, creating hundreds of new jobs and strengthening the U.S. pharmaceutical supply chain.
Jubilant HollisterStier LLC (JHS), a wholly owned subsidiary of Jubilant Pharmova and leading North American pharmaceutical contract manufacturer, has successfully launched its third sterile fill and finish line at its Spokane manufacturing facility in Washington. The $132 million investment represents a significant milestone in the company's multi-phase expansion strategy and brings an additional 50% capacity to the facility.
The launch was marked by the successful production of the inaugural batch, initiating immediate revenue generation from the new line. This development positions JHS to serve the growing demand from global innovator pharmaceutical companies for high-quality sterile injectable manufacturing services.
Advanced Manufacturing Technology
The new line features advanced isolator technology designed to deliver enhanced sterility assurance, throughput and operational precision. Built to meet the highest global regulatory standards, the facility significantly enhances the company's ability to support complex injectable programs across a broad range of therapeutic areas.
"Launching our Third Line is more than a milestone for us," said Chris Preti, CEO - CDMO Sterile Injectables (搜索) at Jubilant HollisterStier. "This expansion also reflects our commitment to continued growth, technological excellence and the community at Spokane."
Capacity Expansion and Market Demand
Together with the commissioning of its upcoming fourth line, JHS is on track to double its total sterile injectable manufacturing capacity at its Spokane facility. The strategic expansion comes at a time when large innovator pharma companies are actively seeking high-quality U.S. manufacturing facilities in the wake of new tariffs imposed by the U.S. government.
"We are witnessing a very strong traction in Requests for Proposals (RFPs) for the New Line," Preti noted. "We expect to reach the full utilization for the New Line in the next 3 years."
Supply Chain Resilience
The investment reinforces JHS's leadership in domestic U.S. pharmaceutical manufacturing and contributes to national health security by helping reduce reliance on offshore supply chains. The expansion is designed to deliver a more resilient and agile pharmaceutical manufacturing ecosystem.
"With Third Line now operational and Fourth Line on the horizon, we are not just doubling our capacity, we're building a future that will create hundreds of new jobs, strengthen the U.S. pharmaceutical supply chain and reaffirm our role as a trusted partner in delivering life-saving therapies to patients around the world," Preti emphasized.
Company Track Record
JHS maintains strong relationships with major pharmaceutical companies, serving as a trusted partner to 5 of the top 20 global pharma companies with a 92% customer retention rate. The company has established a proven track record with regulatory organizations including the U.S. FDA, EMA, PMDA Japan, Health Canada, ANVISA Brazil and other regulatory bodies in over 140 countries worldwide.
The successful launch of the third line positions Jubilant HollisterStier to capitalize on the increasing demand for domestic pharmaceutical manufacturing while supporting the broader goal of supply chain diversification in the pharmaceutical industry.